Payment overview · 2025
General Payments
$1,302.70
58 reported records · 24 companies
Healthcare provider profile · identity verified
Paramjit S. Takhar, MD
Allopathic & Osteopathic Physicians|Family Medicine · SACRAMENTO, CA · NPI 1184791048
Verified facts
What the public records show
CMS Open Payments records show Paramjit S. Takhar, MD received $1,302.70 in general payments during 2025 across 58 reported records.
GlaxoSmithKline, LLC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $197.62 | 15.2% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $151.85 | 11.7% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.02 | 7.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $90.39 | 6.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.39 | 6.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.01 | 5.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.69 | 4.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.59 | 4.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.58 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.25 | 4.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.05 | 3.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.89 | 3.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.23 | 2.6% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $32.13 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.97 | 2.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.51 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.88 | 2.1% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $23.55 | 1.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $22.89 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.21 | 1.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.89 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.27 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.61 | 1.4% | 1 | 2025 |
| Botanix SB Inc | Unresolved — no canonical attribution shown | $17.23 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,272.73 | 57 |
| Long term medical supply or device loan | $29.97 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $171.38 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $120.37 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $116.29 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $90.39 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.69 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.17 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.17 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.59 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.58 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.58 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.57 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.05 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| SOFDRA Normalized: sofdra |
Drug | Botanix SB Inc | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 175 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 38 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2625 | 881 |
| Amlodipine Besylate | Amlodipine Besylate | 1723 | 602 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 1586 | 549 |
| Metformin Hcl | Metformin Hcl | 1387 | 464 |
| Omeprazole | Omeprazole | 1163 | 446 |
| Losartan Potassium | Losartan Potassium | 1035 | 359 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1022 | 389 |
| Glipizide | Glipizide | 1021 | 326 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 979 | 414 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 970 | 325 |
| Donepezil Hcl | Donepezil Hcl | 970 | 354 |
| Levothyroxine Sodium | Levothyroxine Sodium | 960 | 306 |
| Gabapentin | Gabapentin | 875 | 326 |
| Metoprolol Succinate | Metoprolol Succinate | 826 | 284 |
| Naproxen | Naproxen | 678 | 265 |
| Meloxicam | Meloxicam | 666 | 266 |
| Fluticasone Propionate | Fluticasone Propionate | 615 | 245 |
| Sertraline Hcl | Sertraline Hcl | 531 | 190 |
| Tamsulosin Hcl | Tamsulosin Hcl | 496 | 191 |
| Famotidine | Famotidine | 465 | 183 |
| Furosemide | Furosemide | 432 | 152 |
| Trazodone Hcl | Trazodone Hcl | 427 | 166 |
| Januvia | Sitagliptin Phosphate | 411 | 108 |
| Mirtazapine | Mirtazapine | 379 | 142 |
| Azithromycin | Azithromycin | 376 | 251 |
| Ibuprofen | Ibuprofen | 344 | 144 |
| Clonidine Hcl | Clonidine Hcl | 343 | 119 |
| Nitroglycerin | Nitroglycerin | 338 | 145 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 325 | 132 |
| Baclofen | Baclofen | 308 | 133 |
| Prednisone | Prednisone | 300 | 167 |
| Hydrochlorothiazide | Hydrochlorothiazide | 291 | 107 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 283 | 90 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 264 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 117 |
| Clonidine | Clonidine | 243 | 84 |
| Breyna | Budesonide/Formoterol Fumarate | 233 | 97 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 231 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 90 |
| Buspirone Hcl | Buspirone Hcl | 226 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 81 |
| Montelukast Sodium | Montelukast Sodium | 213 | 71 |
| Finasteride | Finasteride | 212 | 89 |
| Alendronate Sodium | Alendronate Sodium | 211 | 78 |
| Carvedilol | Carvedilol | 206 | 76 |
| Diclofenac Sodium | Diclofenac Sodium | 198 | 114 |
| Hydrocortisone | Hydrocortisone | 197 | 95 |
| Pioglitazone Hcl | Pioglitazone Hcl | 196 | 68 |
| Quetiapine Fumarate | Quetiapine Fumarate | 189 | 77 |
| Eliquis | Apixaban | 184 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 66 |
| Allopurinol | Allopurinol | 177 | 59 |
| Potassium Chloride | Potassium Chloride | 177 | 61 |
| Spironolactone | Spironolactone | 177 | 56 |
| Jardiance | Empagliflozin | 175 | 59 |
| Meclizine Hcl | Meclizine Hcl | 171 | 83 |
| Azelastine Hcl | Azelastine Hcl | 169 | 71 |
| Breo Ellipta | Fluticasone/Vilanterol | 169 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 65 |
| Lisinopril | Lisinopril | 160 | 67 |
| Ondansetron Odt | Ondansetron | 155 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 52 |
| Latanoprost | Latanoprost | 140 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 137 | 61 |
| Doxycycline Hyclate | Doxycycline Hyclate | 129 | 86 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 121 | 73 |
| Ketoconazole | Ketoconazole | 118 | 43 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 116 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 110 | 82 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 100 | 41 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 99 | 59 |
| Fenofibrate | Fenofibrate | 98 | 44 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 96 | 45 |
| Trulicity | Dulaglutide | 94 | 38 |
| Loperamide | Loperamide Hcl | 89 | 55 |
| Sumatriptan Succinate | Sumatriptan Succinate | 87 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 86 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 84 | 40 |
| Clobetasol Propionate | Clobetasol Propionate | 76 | 33 |
| Clotrimazole | Clotrimazole | 76 | 46 |
| Fluconazole | Fluconazole | 76 | 51 |
| Simvastatin | Simvastatin | 76 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 75 | 26 |
| Xarelto | Rivaroxaban | 75 | 20 |
| Arnuity Ellipta | Fluticasone Furoate | 74 | 18 |
| Methimazole | Methimazole | 71 | 22 |
| Benzonatate | Benzonatate | 70 | 35 |
| Metronidazole | Metronidazole | 67 | 49 |
| Farxiga | Dapagliflozin Propanediol | 66 | 25 |
| Lactulose | Lactulose | 66 | 23 |
| Amoxicillin | Amoxicillin | 65 | 49 |
| Clonazepam | Clonazepam | 61 | 31 |
| Levetiracetam | Levetiracetam | 61 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 38 |
| Atenolol | Atenolol | 60 | 21 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 60 | 32 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 59 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 34 |
| Colchicine | Colchicine | 57 | 21 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 55 | 16 |
| Megestrol Acetate | Megestrol Acetate | 55 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 26 |
| Entresto | Sacubitril/Valsartan | 54 | 18 |
| Tramadol Hcl | Tramadol Hcl | 54 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 34 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 50 | 14 |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 50 | 19 |
| Ozempic | Semaglutide | 50 | 13 |
| Propranolol Hcl | Propranolol Hcl | 50 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 39 |
| Topiramate | Topiramate | 48 | 14 |
| Cephalexin | Cephalexin | 46 | 38 |
| Haloperidol | Haloperidol | 46 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 24 |
| Linzess | Linaclotide | 46 | 24 |
| Lumigan | Bimatoprost | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 18 |
| Risperidone | Risperidone | 43 | suppressed |
| Glipizide Er | Glipizide | 42 | 16 |
| Memantine Hcl | Memantine Hcl | 42 | 12 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 19 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 39 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 14 |
| Anastrozole | Anastrozole | 38 | 15 |
| Pentoxifylline | Pentoxifylline | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 37 | 17 |
| Aripiprazole | Aripiprazole | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 21 |
| Tradjenta | Linagliptin | 36 | 11 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Ibu | Ibuprofen | 34 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 14 |
| Bumetanide | Bumetanide | 32 | 12 |
| Klor-Con 8 | Potassium Chloride | 32 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 11 |
| Xiidra | Lifitegrast | 31 | 15 |
| Constulose | Lactulose | 30 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 20 |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 29 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | 19 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | 13 |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Tacrolimus | Tacrolimus | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 20 | 17 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | 16 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 15 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | 11 |
| Novolog Flexpen | Insulin Aspart | 17 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Briviact | Brivaracetam | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,302.70 · 58 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, FREESTYLE INSULINX, GEMTESA, JARDIANCE, Kerendia, Korlym, NURTEC ODT, Natroba, OPZELURA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rhapsido, Rybelsus, SHINGRIX, SOFDRA, SPRAVATO, Spinosad, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VTAMA, ZAVZPRET, ZENPEP, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error